Hexagon Capital Partners’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-3,575
| Closed | -$263K | – | 228 |
|
|
2025
Q1 | $263K | Buy |
3,575
+20
| +0.6% | +$1.47K | 0.05% | 173 |
|
|
2024
Q4 | $233K | Sell |
3,555
-1,168
| -25% | -$76.5K | 0.04% | 193 |
|
|
2024
Q3 | $368K | Buy |
4,723
+32
| +0.7% | +$2.49K | 0.07% | 127 |
|
|
2024
Q2 | $366K | Buy |
4,691
+1,447
| +45% | +$113K | 0.08% | 129 |
|
|
2024
Q1 | $220K | Buy |
3,244
+293
| +10% | +$19.9K | 0.05% | 189 |
|
|
2023
Q4 | $199K | Buy |
2,951
+1,136
| +63% | +$76.5K | 0.05% | 198 |
|
|
2023
Q3 | $123K | Sell |
1,815
-288
| -14% | -$19.5K | 0.03% | 233 |
|
|
2023
Q2 | $151K | Buy |
2,103
+479
| +29% | +$34.3K | 0.04% | 200 |
|
|
2023
Q1 | $113K | Buy |
1,624
+142
| +10% | +$9.86K | 0.03% | 226 |
|
|
2022
Q4 | $100K | Buy |
1,482
+205
| +16% | +$13.9K | 0.03% | 243 |
|
|
2022
Q3 | $70K | Buy |
1,277
+544
| +74% | +$29.8K | 0.02% | 300 |
|
|
2022
Q2 | $48K | Buy |
733
+509
| +227% | +$33.3K | 0.01% | 368 |
|
|
2022
Q1 | $15K | Hold |
224
| – | – | ﹤0.01% | 560 |
|
|
2021
Q4 | $13K | Sell |
224
-73
| -25% | -$4.24K | ﹤0.01% | 566 |
|
|
2021
Q3 | $18K | Hold |
297
| – | – | 0.01% | 506 |
|
|
2021
Q2 | $18K | Sell |
297
-36
| -11% | -$2.18K | 0.01% | 474 |
|
|
2021
Q1 | $16K | Buy |
333
+260
| +356% | +$12.5K | ﹤0.01% | 462 |
|
|
2020
Q4 | $3K | Sell |
73
-54
| -43% | -$2.22K | ﹤0.01% | 591 |
|
|
2020
Q3 | $6K | Buy |
+127
| New | +$6K | ﹤0.01% | 509 |
|